| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-514SS | |||
| Azide and BSA Free | NBP2-80785 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-25196SS | |||
| Azide and BSA Free | NBP2-80634 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27216 | |||
| Azide and BSA Free | NBP2-25199SS | |||
| Azide and BSA Free | NBP2-27216-25ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19775SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-24865 | |||
| Azide and BSA Free | NBP2-24865SS | |||
![Immunocytochemistry/Immunofluorescence: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-IGF-II R/IGF2R Antibody (2G11) NB300-514 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/IGF-II-R-IGF2R-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0014.jpg "Immunocytochemistry/Immunofluorescence: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-IGF-II R/IGF2R Antibody (2G11) NB300-514 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Staining of human testis using NB300-514 antibody at 1:100.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunohistochemistry-NB300-514-img0011.jpg)
![Flow Cytometry: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - An intracellular stain was performed on MCF7 cells with IGF-II R/IGF2R [2G11] Antibody NB300-514AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/IGF-II-R-IGF2R-Antibody-2G11-Flow-Cytometry-NB300-514-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6-Phosphate Receptor staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing Mannose 6-Phosphate Receptor at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - HMVEC Cells](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Staining in Hela Cells. Mannose 6-Phosphate Receptor staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Mannose 6-Phosphate Receptor at a dilution of 1:20 over night at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: IGF-II R/Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6 Phosphate Receptor (Cation independent) antibody (2G11) was tested at (1:250) in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight-550 (red).](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0010.jpg)
![Flow Cytometry: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Intracellular flow cytometric staining of 1 x 10^6 MCF-7 cells using Mannose 6 Phosphate Receptor antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Flow-Cytometry-NB300-514-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Immunocytochemistry-Immunofluorescence-NBP2-25196-img0014.jpg "Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.")
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on Ramos cells with CD19 Antibody (CB19) NBP2-26646 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - The CD19 (CB19) antibody was tested in Daudi cells at a 1:40 dilution against Dylight 488 (Green). Actin and nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Immunocytochemistry-Immunofluorescence-NBP2-25196-img0002.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Surface staining of 10^6 human lymphocytes using 0.2 ug of CD19 antibody (red) and isotype control (green). Cell surface staining kit was used for this test.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0001.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the FITC conjugate of NBP2-25196. Staining of CD19 in 10^6 human lymphocytes using 10 ul (0.25 ug) of this antibody. Shaded histogram represents cells without antibody; green represents isotype control ; red represents anti-CD19 antibody.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0007.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the PE conjugate of NBP2-25196. Staining of CD19 in 1x10^6 human PBMC using 10 ul (0.25 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0008.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-25196. Staining of human PBMC. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0009.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the DyLight 405 conjugate of NBP2-25196. Staining of CD19 in human PBMCs using anti-CD19 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0010.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with TACI/TNFRSF13B/CVID (1A1) antibody NB600-1189PE and a matched isotype control. Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-25196AF647.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0011.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with CD9 (HI9a) antibody NB100-77915AF647 and a matched isotype control NBP2-27287AF488. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-26646.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0012.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-27216. Staining of human PBMC. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0007.jpg "Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-27216. Staining of human PBMC. Image from verified customer review.")
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the PE conjugate of NBP2-27216. Staining of CD4 in human PBMC using anti-CD4 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0004.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the FITC conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0011.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the DyLight 405 conjugate of NBP2-27216. Staining of CD4 in human PBMCs using anti-CD4 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0005.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the PE conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of this antibody. Green represents isotype control; red represents anti-CD4 antibody. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0009.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Allophycocyanin conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0010.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) - Azide and BSA Free [NBP2-25199] - analysis of CD4 in human PBMCs using 0.1 ug of this antibody. Secondary antibody is goat anti-mouse PE.](http://images.novusbio.com/fullsize/nbp2-25199_mouse-monoclonal-cd4-antibody-rpa-t4-imgenex-img-5916a-25ug-17720241044654.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-19775-img0004.jpg "Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.")
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody - BSA Free [NBP1-19775] - In situ expression of IL-6 in glomerular and tubulointerstitial compartments in patients with diabetic nephropathy DN (right) and control group (left). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32723296/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody---BSA-Free-Immunohistochemistry-NBP1-19775-img0006.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Staining in the cytoplasm of villi and in the crypt cells of human lung carcinoma tissue.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NBP1-19775-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg)
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Flow (Cell Surface): TLR4 Antibody (MTS510) [NB100-56560] - Analysis using Azide/BSA FREE version of NBP2-24865. Cell surface analysis of TLR4 on mouse RAW cells using 0.5 ug/10^6 cells of TLR4 antibody, anti-rat APC conjugated secondary antibody and cell surface flow kit. Green: isotype control. Red: TLR4 antibody.](http://images.novusbio.com/fullsize/TLR4-Antibody-MTS510-Flow-Cell-Surface-NB100-56560-img0010.jpg "Flow (Cell Surface): TLR4 Antibody (MTS510) [NB100-56560] - Analysis using Azide/BSA FREE version of NBP2-24865. Cell surface analysis of TLR4 on mouse RAW cells using 0.5 ug/10^6 cells of TLR4 antibody, anti-rat APC conjugated secondary antibody and cell surface flow kit. Green: isotype control. Red: TLR4 antibody.")
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using Azide Free version of NB100-56560. Cell surface TLR4 in mouse peritoneal cells. Green: isotype control. Red: anti-TLR4 antibody.](http://images.novusbio.com/fullsize/TLR4-Antibody-MTS510-Flow-Cytometry-NB100-56560-img0009.jpg)
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using the FITC conjugate of NBP2-24865. Staining of TLR4 in mouse peritoneal cells using 1 ug of this antibody. Shaded histogram: Cells without antibody; green represents isotype control; red represents anti-TLR4 antibody.](http://images.novusbio.com/fullsize/TLR4-Antibody-MTS510-Flow-Cytometry-NB100-56560-img0012.jpg)
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using the PE conjugate of NBP2-24865. Staining of cell surface TLR4 using this antibody at 0.625 ug/10^6 Raw cells (pretreated with anti-CD16/32). Shaded histogram: isotype control.](http://images.novusbio.com/fullsize/TLR4-Antibody-MTS510-Flow-Cytometry-NB100-56560-img0011.jpg)
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using the PE conjugate of NBP2-24865. Staining of TLR4 in mouse peritoneal cells using 0.5 ug of this antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents anti-TLR4 antibody.](http://images.novusbio.com/fullsize/nb100-56560_rat-monoclonal-tlr4-antibody-mts510-17720249362619.jpg)
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using the FITC conjugate of NBP2-24865. Staining of TLR4 in RAW cells using 0.5 ug of this antibody. Black histogram represents cells without antibody; green represents isotype control; red represents anti-TLR4 antibody.](http://images.novusbio.com/fullsize/nb100-56560_rat-monoclonal-tlr4-antibody-mts510-17720241003224.jpg)
![Flow Cytometry: TLR4 Antibody (MTS510) [NB100-56560] - Analysis using the FITC conjugate of NBP2-24865. Staining of TLR4 in mouse peritoneal cells using 1 ug of this antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents anti-TLR4 antibody.](http://images.novusbio.com/fullsize/nb100-56560_rat-monoclonal-tlr4-antibody-mts510-17720241003220.jpg)
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Formalin fixed paraffin embedded human tonsil stained with CD163 antibody (NB110-59935).](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0003.jpg "Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Formalin fixed paraffin embedded human tonsil stained with CD163 antibody (NB110-59935).")
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Human tonsil.](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0001.jpg)
![Immunohistochemistry-Paraffin: CD163 Antibody (10D6) [NB110-59935] - Human lymph node stained with CD163 antibody showing cytoplasmic staining in non-germinal center cells. Image from verified customer review.](http://images.novusbio.com/fullsize/CD163-Antibody-10D6-Immunohistochemistry-Paraffin-NB110-59935-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) [NB600-1066] - TcdA colocalizes with PACSIN2 during entry in Caco-2 cells. Immunofluorescence assays were performed as described in Fig 1B. At indicated time points, cells were fixed, stained for PACSIN2 and analyzed by confocal microscopy. Merged images show PACSIN2 in red, toxin in green and colocalization in yellow. The images shown are representative of multiple fields imaged from three independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Clostridium-Difficile-Toxin-A-Antibody-PCG4-1-Immunocytochemistry-Immunofluorescence-NB600-1066-img0007.jpg "<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) [NB600-1066] - TcdA colocalizes with PACSIN2 during entry in Caco-2 cells. Immunofluorescence assays were performed as described in Fig 1B. At indicated time points, cells were fixed, stained for PACSIN2 and analyzed by confocal microscopy. Merged images show PACSIN2 in red, toxin in green and colocalization in yellow. The images shown are representative of multiple fields imaged from three independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) [NB600-1066] - TcdA and TcdB utilize distinct endocytic mechanisms to intoxicate colonic epithelial cells. TcdA does not colocalize with clathrin heavy chain during cell entry. Caco-2 cells on glass coverslips were chilled at 10C for 45 min and then exposed to media containing 50 nM TcdA-546 or buffer (no toxin control). The toxin was allowed to bind to cells for 45 min at 10C. Unbound toxin was removed, and cells were shifted to 37C to allow internalization of toxin for the times shown. At each time point, cells were washed once with pre-warmed PBS, fixed and stained for CHC, and imaged by confocal microscopy. Merged images show clathrin in red and toxin in green. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Clostridium-Difficile-Toxin-A-Antibody-PCG4-1-Immunocytochemistry-Immunofluorescence-NB600-1066-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) [NB600-1066] - Depletion of PACSIN2 inhibits TcdA entry in Caco-2 cells. Caco-2 cells expressing non-targeting shRNA (Ctrl shRNA) or shRNA 982 targeting PACSIN2 were incubated with 50 nM TcdA-546 at 10C for 45 min. Unbound toxins were removed and cells were shifted to 37C to allow internalization. After 20 min, cells were washed, fixed, stained for PACSIN2 and imaged by confocal microscopy. PACSIN2 and TcdA staining from ctrl shRNA and sh982 expressing cells are shown. The images shown are representative of multiple fields imaged from three independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Clostridium-Difficile-Toxin-A-Antibody-PCG4-1-Immunocytochemistry-Immunofluorescence-NB600-1066-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) - BSA Free [NB600-1066] - PACSIN2 is required for TcdA uptake & toxin-induced rounding in wildtype MEF cells. (C), (D) & (E). Depletion of PACSIN2 reduces TcdA uptake in MEF cells. Wildtype MEF cells expressing luciferase (luc) or PACSIN2 siRNA incubated with 50 nM TcdA-546 at 10°C for 45 min. Cells allowed to warm up to 37°C for 2 min & then washed to remove unbound toxins & incubated with fresh media prewarmed to 37°C. Bound toxins allowed to internalize for 9 min at 37°C. Cells then fixed, stained for PACSIN2 & imaged by confocal microscopy. PACSIN2 & TcdA-546 staining from each condition shown in (C). Scale bars, 10 μm. The images shown representative of multiple fields imaged from two independent experiments. (D) Comparison of mean fluorescence intensities of PACSIN2 between luc & PACSIN2 siRNA transfected cells. Data represent mean & SD of 101 individual cells. Student’s t test ***p<0.0001. (E) Comparison of mean fluorescence intensities of TcdA-546 between luc & PACSIN2 siRNA transfected cells. Data represent mean & SD of 101 individual cells. Student’s t test ***p<0.0001. Cells chosen at random for intensity analyses. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1066_mouse-monoclonal-clostridium-difficile-toxin-a-antibody-pcg4-1-310202416173511.jpg)
![Immunocytochemistry/ Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) - BSA Free [NB600-1066] - TcdA colocalizes with PACSIN2 in wildtype MEF cells.(A) Wildtype MEFs on glass coverslips were allowed to bind 50 nM TcdA-546 for 45 min at 10°C, & cells were shifted to 37°C to allow internalization of toxin for 3 min. Cells were fixed, stained for PACSIN2, & analyzed by confocal microscopy. Merged images show PACSIN2 in red, toxin in green, & colocalization in yellow. Scale bars, 10 μm. The images shown are representative of multiple fields imaged from two independent experiments. (B) Immunofluorescence assays were performed as described in (A), but cells were stained for cav1 in addition to PACSIN2. Merged images show PACSIN2 in red, toxin in green, & cav1 in blue. Yellow puncta in merged images denote TcdA- & PACSIN2-positive structures. Pink punta denote caveolae-associated PACSIN2. Scale bars, 10 μm. (C) Pearson’s correlation coefficient to assess the extent of colocalization between PACSIN2, cav1 & TcdA-546 after 3 min toxin uptake. Data represent mean & SD of 31 individual cells chosen at random. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1066_mouse-monoclonal-clostridium-difficile-toxin-a-antibody-pcg4-1-310202416182624.jpg)
![Immunocytochemistry/ Immunofluorescence: Clostridium Difficile Toxin A Antibody (PCG4.1) - BSA Free [NB600-1066] - TcdA colocalizes with PACSIN2 in wildtype MEF cells.(A) Wildtype MEFs on glass coverslips were allowed to bind 50 nM TcdA-546 for 45 min at 10°C, & cells were shifted to 37°C to allow internalization of toxin for 3 min. Cells were fixed, stained for PACSIN2, & analyzed by confocal microscopy. Merged images show PACSIN2 in red, toxin in green, & colocalization in yellow. Scale bars, 10 μm. The images shown are representative of multiple fields imaged from two independent experiments. (B) Immunofluorescence assays were performed as described in (A), but cells were stained for cav1 in addition to PACSIN2. Merged images show PACSIN2 in red, toxin in green, & cav1 in blue. Yellow puncta in merged images denote TcdA- & PACSIN2-positive structures. Pink punta denote caveolae-associated PACSIN2. Scale bars, 10 μm. (C) Pearson’s correlation coefficient to assess the extent of colocalization between PACSIN2, cav1 & TcdA-546 after 3 min toxin uptake. Data represent mean & SD of 31 individual cells chosen at random. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006070), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1066_mouse-monoclonal-clostridium-difficile-toxin-a-antibody-pcg4-1-310202416175252.jpg)
![Immunohistochemistry-Paraffin: Melan-A/MART-1 Antibody (A19-P) [NBP1-30151] - Confocal microscopy image of human fetal inner ear tisue section stained with Melan-A antibody (green), 1:200 dilution, incubated over night. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Melan-A-MART-1-Antibody-A19-P-Immunohistochemistry-Paraffin-NBP1-30151-img0012.jpg "Immunohistochemistry-Paraffin: Melan-A/MART-1 Antibody (A19-P) [NBP1-30151] - Confocal microscopy image of human fetal inner ear tisue section stained with Melan-A antibody (green), 1:200 dilution, incubated over night. IHC-P image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: Melan-A/MART-1 Antibody (A19-P) [NBP1-30151] - Human tissue (4 um section) stained with anti - Melan A monospecific clonal antibody.](http://images.novusbio.com/fullsize/Melan-A-MART-1-Antibody-A19-P-Immunohistochemistry-Paraffin-NBP1-30151-img0011.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0006.jpg "Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power")
![Flow Cytometry: CD8 Antibody (YTS105.18) [NB200-578] - Staining of mouse spleen cells.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Flow-Cytometry-NB200-578-img0003.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of Mouse lymph node cryosection with CD8 Antibody and HRP-conjugated goat anti-rat IgG. Low power magnification.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0005.jpg)
